

#4
1/22/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Pierre LEROY

Application No.: Rule 53(b) Cont. Appln. of
Appln. No. 08/809,110, filed March 31, 1997

Filed: August 13, 2001

For: NOVEL IMPLANT AND NOVEL
VECTOR FOR THE TREATMENT OF
ACQUIRED DISEASES

Group Art Unit: Unassigned

Examiner: Unassigned



**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:


Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: August 13, 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Pierre LEROY)	Group Art Unit: unassigned
)	
Application No.: Continuation of)	Examiner: unassigned
Application. No. 08/809,110)	
)	
Filed: August 13, 2001)	
)	
For: NOVEL IMPLANT AND NOVEL)	
VECTOR FOR THE TREATMENT OF)	
ACQUIRED DISEASES)	

11040 U.S. PTO
09/02/93
08/13/01

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicant hereby submits the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited in Application No. 08/809,110 upon which is based a claim for priority under 35 U.S.C. § 120 are not enclosed herewith because copies of the listed documents were previously submitted or cited in prior application Serial No. 08/809,110, filed March 31, 1997, upon which Applicant relies for the benefits provided in 35 U.S.C. § 120.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

5,219,740	Miller et al.	6-15-1993
2 706 486	France	12-23-1994
94/19017	WO	9-1-1994
93/03143	WO	2-18-1993
92/15676	WO	9-17-1992

94/06920	WO	3-31-1994
90/01550	WO	2-22-1990
94/10323	WO	5-11-1994

Chen et al., "Intracellular Antibodies as a New Class of Therapeutic Molecules for Gene Therapy", HUMAN GENE THERAPY, (1994), Vol. 5, No. 5, pp. 595-601, New York, NY, Mary Ann Liebert Inc., Los Angeles, USA

D. Moritz et al, "Cytotoxic T Lymphocytes With a Grated Recognition Specificity for ERBB2-Expressing Tumor Cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, May 1994, pp. 4318-4322, Vol. 91, No. 10, 10 Washington, D.C., USA

A. Conley et al., "Neutralization of Divergent Human Immunodeficiency Virus Type 1 Variants and Primary Isolates by IAM-41-2F5, an Anti-gp41 Human Monoclonal Antibody", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, April 1994, pp. 3348-3352, Vol. 91, No. 8, 12 Washington D.C..

M. Rosenfeld et al., "E1-E3 Replication Deficient Recombinant Adenovirus Vector Containing the Human Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) cDNA Does Not Replicate in Human Respiratory Epithelial Cells" JOURNAL OF CELLULAR BIOCHEMISTRY, SUPPLEMENT, April 1993, page 251, No. 17, Part E, 29-25 New York, NY, USA.

Crystal, R.G., Science, Vol. 270, pages 404-410, (1995), AAAS, Washington D.C., USA.

Orkin et al. NIH Report on the Investment in Research on Gene Therapy, (12/1995), NIH, USA.

Verma et al., Nature, Vol. 389, pp. 239-242, (9/1997), MacMillin, London.

Anderson, W.F., Nature, Vol. 392, Suppl. pp. 25-30, (4/1998).

Brinkmann et al., Proc. Natl. Acad. Sci., U.S.A., Vol. 88, pp. 8616-8620, (10/1991).

Batra et al., Molecular and Cellular Biology, Vol. 11(4): pp. 2200-2205.

Chaudhary et al. Proc. Natl. Acad. Sci., U.S.A., Vol. 87, pp. 9491-9494, (12/1990).

Marshall, E.M., Science, Vol. 269, pp. 1050-1055, (8/1995).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: August 13, 2001